Summary The activity of a new nitrosourea (TCNU) based on the endogenous amino acid taurine was assessed in three human lung cancer xenografts growing in immunodeficient mice. Moderate activity (specific growth delays of 0.63 and 1.13 compared with controls) was seen in two non-small cell tumours after a single oral administration of 20 mg -1kg. This dose was curative in a small cell xenograft. By using high performance liquid chromatography it was possible to detect parent drug in the tumours as well as the plasma and tissues after oral administration of TCNU. Drug sensitivity was correlated inversely with the amount of the DNA repair enzyme 06-methylguanine-DNA methyltransferase assayed from extracts of the tumour cells but not with the levels of parent drug within the tumour. This compound appears to have unique pharmacokinetic properties compared with other chloroethylnitrosoureas.
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Chloroethylnitrosoureas have been used as anti-cancer treatments for many years. The initial enthusiasm generated by impressive activity in preclinical screening models has been tempered by modest anti-tumour activity in man and the problem of delayed cumulative myelosuppression (Weiss & Issell, 1982; Mitchell & Schein, 1986) . Despite this they have been used in a number of malignancies and their ability to cross the blood-brain barrier has led to interest in their activity against malignant gliomas (Walker et al. 1980) . Unfortunately little is known of the pharmacokinetics of the nitrosoureas as it is only recently that techniques have been available to study the plasma levels of the parent drugs and their metabolites (Lee et al., 1985) .
The cytotoxicity of the nitrosoureas is thought to be mediated predominantly by the alkylation of reactive sites on nuclear proteins and by the production of lethal interstrand DNA crosslinks through an 06 alkylguanine intermediate (Tong, et al., 1982) . Repair of these intermediates is carried out by 06-methylguanine-DNA methyltransferase (Robins et al., 1983) and cells deficient in this enzyme (Mer-cells) are more sensitive to damage by chloroethylating agents (Scudiero et al., 1984) . Structure-activity studies have shown considerable variation amongst different nitrosoureas and recently attempts have been made to improve the therapeutic index of the nitrosoureas by producing analogues with novel carrier groups (Johnston & Montgomery, 1986) . (Gunnarson et al., 1988; Smyth et al., 1987) . Other nitrosoureas such as CCNU cannot be detected in the plasma (Lee et al., 1985) . Anti-tumour activity has been reported in vitro against human colonic and small cell lung cancer cell lines (Roed et al., 1987; Hartley-Asp et al., 1988) and in vivo against a variety of transplantable murine tumours (Bibby & Double, 1987; Hartley-Asp et al., 1988) . No studies describing its activity in vivo against human tumours have yet been reported. The validity of a human tumour system for assessing drugs in lung cancer has been established by direct xenograft-patient comparisons (Shorthouse et al., 1980 
Materials and methods

Immunosuppressed mice
Thymectomy was performed by retrosternal aspiration on 3 week old male CBA/Lac mice shortly after weaning. Three weeks later they underwent whole body X-irradiation (7.35 Gy via a 250 kVp, 15 mA source with a Thoraeus Ii filter at 0.37 Gy min-I + 2%). Cytosine arabinoside 200 mg kg 1 i.p. was given 48 h prior to irradiation to protect the bone marrow and gastrointestinal tract. Human bronchial tumour fragments (I mm3) were implanted subcutaneously into each flank the day following irradiation. Neomycin and terramycin were added to the drinking water for the next 14 days to reduce the incidence of septicaemia from gut flora. The animals were housed in conventional conditions in a separate room in the animal unit.
Tumour xenografts Three human bronchial tumours were used for drug testing, their growth characteristics have been described previously (Fergusson et al., 1986) . (i) CX117 a poorly differentiated adenocarcinoma obtained at thoracotomy, (ii) NX002 a moderately differentiated squamous carcinoma grown from an endo-bronchial bronchoscopic biopsy, (iii) NX004 an undifferentiated small cell tumour obtained from a subcutaneous metastasis. All tumours had a doubling time of 10-13 days. Experiments were performed between the 8th and 10th passage for CX117 and NX002 and at the 3rd passage for NX004. All tumours maintained their original histological characteristics on serial passage.
Chemotherapeutic assessments Xenografts were measured three times weekly with calipers and tumour volumes calculated assuming an ellipsoid shape (volume = H/6 x longest diameter x shortest diameter2). Groups of 6-10 tumours attaining a volume of 0.25-1.Ocm3 were selected for drug testing and allocated by restricted randomisation to treatment or control groups. The median doubling time (Td) was estimated for each group and the therapeutic response was expressed in terms of the specific growth delay (SGD) using the equation:
The SGD represents the number of doubling times delayed by treatment (Kopper & Steel, 1975) .
TCNU was kindly provided by Leo AB (Helsingborg, Sweden). It was dissolved in polyethylene glycol (PEG400) and given by oral gavage at a dose of 20 mg kg-1. This maximum tolerated dose was calculated from LD10 experiments using immune deficient mice. The LD10 dose in this system was 25mg kg-1.
Results
Activity in xenografts TCNU given orally (20mg kg-1) caused a delay in the growth of all three xenografts (Figure 1 ). Moderate activity (SGDs of 0.63 and 1.13) was seen in the two non small cell tumours CX1 17 and NX002 (Table I ). TCNU at this dose was curative (no tumour palpable 30 days after treatment) in the small cell xenografts NX004 and in a subsequent experiment, 50% of that dose (10mgkg-1 orally), was also curative in this tumour. No treatment deaths or significant toxicity were observed in any group.
DNA repair enzyme assays
Xenografts were removed using sterile techniques and immediately snap frozen in liquid nitrogen to be stored at -80°C until assayed. Tumours were quickly thawed and minced with scissors to a slurry before the addition of equal volumes of 300mM KC1, 50mM Tris HC1 (pH 7.5), 10mM dithiothreitol, 1 mM EDTA and 0.5 mM phenylmethylsulfonyl fluoride. Cells were disrupted in a Potter hand homogenizer and debris removed by centrifugation (l0,OOOg for 30 min). Protein concentrations were estimated by the Coomassie Blue method (Bradford, 1976) . 06-methylguanine-DNA methyltransferase activity in the extracts was assayed by measurement of the disappearance of 06-[3H] methylguanine from methylated DNA (Karran et al., 1979) . The reaction mixture (500 p1) consisted of DNA containing 1,500 cpm (1.2 pmol 06-methylguanine) in 70 mM Hepes KOH (pH 7.6), 1 mM EDTA, 10mM dithiothreitol, 5% glycerol and 25-300 ig of crude cell protein extract. Mixtures were incubated at 37°C for 1 h then chilled and precipitated with 500,1 cold 0.8 M trichloroacetic acid. After standing at 0°C for 15 min, the samples were centrifuged and the supernatants discarded. The pellets were hydrolysed in 100l i of 0.1 M HC1 at 70°C for 30 min to release all purines from the DNA. Determination of the HC1 soluble radioactive material provided estimates of the relative content of 06_ methylguanine.
The activity of 3-methyladenine-DNA glycosylase was assayed using calf thymus DNA treated with [3 H] dimethyl sulphate as substrate (Riazuddin & Lindahl, 1978) . The reaction mixture (100I ) consisted of lOg alkylated DNA (5,000cpm) in 70mM Hepes KOH (pH7.6), 1mM EDTA, 1mM dithiothreitol, 5% glycerol and 12-100 g crude cell protein extract. Mixtures were incubated at 37°C for 45min and then chilled before the addition of lO,ul heat denatured calf thymus DNA (2mg/ml), lO ul of 5M NaCl and 300pI ethanol. The tubes were mixed and after standing at 0°C for 30min were centrifuged at 10,OOOg for 30min). The supernatant (200pl) was removed and its radioactivity determined.
TCNU assay TCNU was dissolved in PEG 400 and administered by gavage at 20mg kg-1 to 20 fasted tumour bearing mice (10, NX002; 10, NX004). PEG400 alone was given in the same volume to a control group. Samples of venous blood, tumour and lung tissue were taken from each group at 10 and 30min following drug administration. Individual blood specimens were pooled before the plasma was separated by centrifugation at 4°C for 10min at 2,500rpm. Aliquots were stored at -40°C until analysis. Tumours and lungs were removed, washed in cold 0.1 M phosphate buffer (pH 6.0), blotted dry, weighed, frozen in liquid nitrogen and stored at -40°C. Prior to analysis tumours and lungs were homogenised in cold 0.1 M phosphate buffer (pH 6.0) to give a 20% weight/volume homogenate. Analysis of TCNU in plasma and homogenates was by high pressure liquid chromatography using the method of Polacek et al., 1988 with a modified mobile phase of 0.1% glacial acetic acid in water/acetonitrile (63/37).
The results of the assays of the two DNA repair enzymes are illustrated in Figure 2 . Demethylation of 06-methylguanine from alkylated DNA was demonstrated with crude cell extracts prepared from the two non-small cell xenografts NX002 and CX I 17. These tumours clearly possess the enzyme 06-methylguanine-DNA methyltransferase and could be designated Mer+. NX004, the small cell tumour showed no methyltransferase activity and could be designated Mer-. This tumour was cured by TCNU. Extracts from all three xenografts released 3-methyladenine from alkylated DNA (Figure 2b ) demonstrating the presence of the 3-methyladenine-DNA glycosylase enzyme. This confirmed that the Mer-result from NX004 was not due to the sample being inactive.
TCNU assay
Parent TCNU was detectable in the plasma, lungs and tumours of mice lOmin after oral administration (Table II) . Mean plasma levels fell to-30% of their lOmin value by (Steel et al., 1983) . The small cell tumour NX004 appeared to be acutely sensitive to TCNU. This effect may be explained by the fact that this tumour lacks the DNA repair protein 06-methylguanine-DNA methyltransferase and presumably was unable to inhibit the formation of DNA crosslinks caused by the drug. This enzyme is found in foetal and adult human cells (Waldstein et al., 1982; D'Ambrosio et al., 1987) with a marked variation noted between individuals (Myrnes et al., 1983) . Mer -ve cells are more sensitive to nitrosoureas than Mer +ve cells (Day et al., 1980; Erickson et al., 1980) and clearly the therapeutic index of these drugs may depend on the relative activity of this enzyme in malignant and nonmalignant tissues. Myrnes and colleagues (1984) examined this relationship in 24 patients and found that in the majority of cases, enzyme activity was higher in extracts from tumours compared with normal cells from the same organs. It has also been shown recently in mice (Gerson et al., 1987) that bone marrow precursors have low enzyme levels which may explain why myelosuppression is often the dose limiting toxicity observed with nitrosoureas. TCNU appears to have unique pharmacokinetic properties compared with other nitrosoureas (Lee et al., 1985; Gunnarsson et al., 1988) . Using an HPLC technique we were able to demonstrate parent drug in plasma and tissues 10min after an oral dose. TCNU levels fell rapidly in the next 20min with no drug detectable after 1 h. Studies looking for metabolites of TCNU are currently in progress and evidence for its ability to cross the blood-brain barrier will soon be published (Whittle et al., (1987) .
Our studies suggest that TCNU is an interesting compound with unique pharmacokinetic properties. It remains to be seen whether the promising activity seen in preclinical and phase I testing VibePetersen et al., 1987) will be confirmed in the extensive phase II trials which are now ongoing.
